Relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism,angiographically defined coronary artery disease and myocardial infarction in patients with type 2 diabetes mellitus
Restricted accessResearch articleFirst published online December, 2012
Relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism,angiographically defined coronary artery disease and myocardial infarction in patients with type 2 diabetes mellitus
The insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene has been implicated in the pathogenesis of cardiovascular diseases. The objective of the present study was to investigate the influence of ACE gene I/D polymorphism on the development and progression of coronary artery disease (CAD) and myocardial infarction (MI) in type 2 diabetic (T2DM) patients.
Materials and Methods:
We screened 283 T2DM patients, inclusive of 160 patients with angiographically defined CAD, 73 patients with MI, 89 patients without MI and 121 T2DM individuals with no evidence of CAD for ACE gene I /D polymorphism.
Results:
There was no significant difference in the distribution of genotypes and alleles of ACE gene I/D polymorphism between T2DM+CAD and T2DM (non-CAD) groups. However, a significant association of this polymorphism with MI in T2DM+CAD patients (p=0.024) was observed. Further analysis revealed that the frequencies of the DD and ID genotypes increased with the number of stenosed coronary vessels (p=0.026). The DD genotype and the D allele were more frequent in the subgroup of T2DM patients with multivessel CAD (p=0.01) than in individuals with single vessel stenosis.
Conclusions:
These findings reveal a significant relationship between ACE gene I/D polymorphism, multivessel CAD and also the occurrence of MI in T2DM individuals with significant coronary stenoses in our population.
BeckmanJACreagerMALibbyP. Diabetes and atherosclerosis. Epidemiology, pathophysiology and management. JAMA2002; 287: 2570–2581.
2.
HauserERPericak-VanceMA. Genetic analysis for common complex disease. Am Heart J2000; 140: 36–44.
3.
PfefferM. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers. Am Heart J2000; 139: S23–S28.
4.
FoxKM. European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet2003; 362: 782–788.
5.
YusufSSleightPPogueJ. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med2000; 342: 145–153.
6.
KranzhoferRSchmidtJPfeifferCA. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol1999; 19: 1623–1629.
7.
WarnholtzANickenigGSchulzE. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation1999; 99: 2027–2033.
8.
RigatBHubertCAlhenc-GelasF. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest1990; 86: 1343–1346.
9.
CambienFPoirierOLecerfL. Deletion polymorphism in the gene for angiotensin- converting enzyme is a potent risk factor for myocardial infarction. Nature1992; 359: 641–644.
10.
KeavneyBDDudleyCRKStrattonIM. UK Prospective Diabetes Study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM. Diabetologia1995; 38: 948–952.
11.
ChuangLMChiuKCChiangFT. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients with hypertension, non-insulin-dependent diabetes mellitus, and coronary heart disease in Taiwan. Metabolism1997; 46: 1211–1214.
12.
KlemmTMittrach-SchorinSNeumannS. No association between the angiotensin-converting-enzyme gene insertion/deletion polymorphism and the occurrence of macroangiopathy in patients with diabetes mellitus type 2. Horm Metab Res2003; 35: 43–47.
13.
GrammerTBRennerWvon KargerS. The angiotensin-I converting enzyme I/D polymorphism is not associated with type 2 diabetes in individuals undergoing coronary angiography. (The Ludwigshafen Risk and Cardiovascular Health Study). Mol Genet Metab2006; 88: 378–383.
14.
GanesanMBhaskarSManiR. The relationship of ACE and CETP gene polymorphisms with cardiovascular disease in a cohort of Asian Indian patients with and those without type 2 diabetes. J Diabetes Complications2011; 25: 303–308.
15.
RuizJBlancheHCohenN. Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin- dependent diabetes mellitus. Proc Natl Acad Sci USA1994; 91: 3662–3665.
16.
FujisawaTIkegamiHShenGQ. Angiotensin I—converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM. Diabetes Care1995; 18: 983–985.
17.
WuSSGuoQMLiuGL. The relationship of angiotensin I-converting enzyme gene polymorphism with diabetic retinopathy and diabetes myocardial infarction. Zhonghua Yi Xue Yi Chuan Xue Za Zhi2004; 21: 283–285.
18.
LahiriDKNurnbergerJI. A rapid nonenzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nuc Acids Res1991; 19: 5444.
19.
ZintzarasE. The generalized odds ratio as a measure of genetic risk effect in the analysis and meta-analysis of association studies. Stat Appl Genet Mol Biol2010; 9: Article21.
20.
PowellJSClozelJRMullerRKM. Inhibitors of angiotensin- converting enzyme prevent myointimal proliferation after vascular injury. Science1989; 245: 186–188.
21.
WangYNgMCSoWY. Prognostic effect of insertion/deletion polymorphism of the ACE gene on renal and cardiovascular clinical outcomes in Chinese patients with type 2 diabetes. Diabetes Care2005; 28: 348–354.
22.
HuangXHRantalaihoVWirtaO. Angiotensin-converting enzyme gene polymorphism is associated with coronary heart disease in non-insulin-dependent diabetic patients evaluated for 9 years. Metabolism1998; 47: 1258–1262.
23.
UkkolaOSavolainenMJSalmelaPI. Insertion/deletion polymorphism in the angiotensin- converting enzyme gene associated with macroangiopathy and blood pressure in patients with non-insulin-dependent diabetes mellitus. J Mol Med1995; 73: 307–311.
24.
ZintzarasERamanGKitsiosG. Angiotensin-converting enzyme insertion/deletion gene polymorphic variant as a marker of coronary artery disease: a meta-analysis. Arch Intern Med2008; 168: 1077–1089.
25.
JosephANairKGAshavaidTF. Angiotensin converting enzyme gene polymorphism in coronary artery disease: the Indian scenario. Clin Chem Lab Med1998; 36: 621–624.
26.
PandeyUKumariRNathB. Association of angiotensin- converting enzyme, methylene tetrahydrofolate reductase and paraoxonase gene polymorphism and coronary artery disease in an Indian populationCardiol J2011; 18: 385–394.
27.
NakaiKItohCMiuraY. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese. Circulation1994; 90: 2199–2202.
28.
SiguschHHVogtSGruberU. Angiotensin-I-converting enzyme DD genotype is a risk factor of coronary artery disease. Scand J Clin Lab Invest1997; 57: 127–132.
29.
GardemannAWeissTSchwartzO. Gene polymorphism but not catalytic activity of angiotensin I-converting enzyme is associated with coronary artery disease and myocardial infarction in low-risk patients. Circulation1995; 92: 2796–2799.
30.
JeunemaitreXLedruFBattagliaS. Genetic polymorphisms of the renin-angiotensin system and angiographic extent and severity of coronary artery disease: the CORGENE study. Hum Genet1997; 99: 66–73.
DanserAHSchalekampMABaxWA. Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation1995; 92: 1387–1388.
33.
DietFPrattREBerryGJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation1996; 94: 2756–2767.
34.
HirschATTalsnessCESchunkertH. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res1991; 59: 475–482.
35.
GuzikTJWestNEBlackE. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res2000; 86: E85–E90.
36.
CrespoMJMoretaSGonzálezJ. Cardiovascular deterioration in STZ-diabetic rats: possible role of vascular RAS. Pharmacology2003; 68: 1–8.
37.
LimHSMacFadyenRJLipGY. Diabetes mellitus, the renin-angiotensin aldosterone system, and the heart. Arch Intern Med2004; 164: 1737–1748.
38.
CosterousseOAllegriniJLopezM. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J1993; 290: 33–40.
TopolEJ. The genomic basis of myocardial infarction. J Am Coll Cardiol2005; 46: 1456–1465.
41.
HackamDGAnandSS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA2003; 290: 932–940.
42.
BaeJHBassengeEKimKB. Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis2001; 155: 517–523.
43.
ColhounHMBetteridgeDJDurringtonPN. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004; 364: 685–696.
44.
PriceJFMowbrayPILeeAJ. Relationship between smoking and cardiovascular risk factors in the development of disease: Edinburgh Artery Study. Eur Heart J1999; 20: 344–353.
